Petri dish)

Research and Development

Current R&D Areas of Focus in Transplantation

Currently we are researching therapies to address major complications following transplantation, with three active programs focused on transplant rejection.

Solid Organ Transplantation

Product Clinical Development Description
CSL842 C1-INH AMR Phase III Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as Adjunctive Treatment For Refractory Antibody-Mediated Rejection (ARMOR) in Adult Renal Transplant Recipients. Learn More
Clazakizumab (Partnership with Vitaeris Inc.) Phase III Interleukin 6 blockade Modifying Antibody mediated Graft INjury and eGFR decline (IMAGINE) Learn More

Stem Cell Transplantation

Product Clinical Development Description
CSL964 AAT GvHD Phase II/III Immunomodulation by Alpha-1 Antitrypsin to Enable Prevention of GVHD (MODULAATE) in Patients Receiving Hematopoietic Cell Transplant. Learn More